Anyplex II HPV test in detection and follow-up after surgical treatment of CIN2+ lesions.
Adult
Cervix Uteri
/ pathology
Early Detection of Cancer
Female
Genotype
Humans
Molecular Diagnostic Techniques
/ instrumentation
Papillomaviridae
/ classification
Papillomavirus Infections
/ complications
Reagent Kits, Diagnostic
/ standards
Sensitivity and Specificity
Uterine Cervical Neoplasms
/ pathology
Viral Load
/ methods
Uterine Cervical Dysplasia
/ pathology
HPV
cervical intraepithelial neoplasia
follow-up
genotyping
real time PCR
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
15
01
2021
received:
27
08
2020
accepted:
04
02
2021
pubmed:
11
2
2021
medline:
30
12
2021
entrez:
10
2
2021
Statut:
ppublish
Résumé
Human papillomavirus (HPV) tests differ for technology, targets, and information on the genotype and viral load. In this study, we evaluated the performance of the Seegene Anyplex II HPV HR (Anyplex) assay in the detection of cervical intraepithelial lesions (CIN) and as a test-of-cure in the follow-up after surgical treatment. One hundred and sixty-seven women referred to the European Institute of Oncology, Milan, for surgical treatment of CIN2+ were enrolled. A cervical sample was taken before treatment and at the first follow-up visit: on these samples, Qiagen Hybrid Capture 2 (HC2), Roche Linear Array HPV Test (Linear Array), cytology and histology were performed at baseline, HC2, and cytology at follow-up. Anyplex genotyping HPV test was performed on a post aliquot from liquid-based cytology specimens when available. The concordance between Anyplex and HC2 was 93.6% at baseline and 76.7% at follow-up (3-9 months after treatment), respectively. The concordance between Anyplex and Linear Array was evaluable only at baseline (92.9%). No recurrence occurred in women without the persistence of the same genotype at follow-up. Seven women relapsed: six had persistence of the same genotypes (five HPV16, one HPV33, and one HPV39), while one tested negative not only with Anyplex but also with HC2 for the persistence of low-risk genotype infection (HPV73 only detected by Linear Array). Anyplex test represents a valid option for HPV detection and genotyping in order to stratify women at risk of high-grade lesions at baseline and to monitor patients treated for CIN2+ lesions during follow-up.
Substances chimiques
Reagent Kits, Diagnostic
0
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6340-6346Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology. 2009;384:260-265.
Kjaer SK , Frederiksen K , Munk C , Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102:1478-1488.
Katki HA , Schiffman M , Castle PE , et al. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S78-S84.
Cuschieri K , Bhatia R , Cruickshank M , Hillemanns P , Arbyn M. HPV testing in the context of post-treatment follow up (test of cure). J Clin Virol. 2016;76(Suppl 1):S56-S61.
Poljak M , Kocjan BJ , Oštrbenk A , Seme K. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Virol. 2016;76(Suppl 1):S3-S13.
Mariani L , Sandri MT , Preti M , et al. HPV-testing in follow-up of patients treated for CIN2+ lesions. J Cancer. 2016;7(1):107-114.
Cubie HA , Canham M , Moore C , Pedraza J , Graham C , Cuschieri K. Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish Test of Cure Study (STOCS-H). J Clin Pathol. 2014;67(6):458-463.
Van der Heijden E , Lopes AD , Bryant A , Bekkers R , Galaal K. Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): impact of human papillomavirus (HPV) test. Cochrane Database Syst Rev. 2015;1(1):CD010757.
Bottari F , Iacobone AD , Passerini R , et al. Human papillomavirus genotyping compared with a qualitative high-risk human papillomavirus test after treatment of high-grade cervical intraepithelial neoplasia: a systematic review. Obstet Gynecol. 2019;134(3):452-462.
Demarco M , Hyun N , Carter-Pokras O , et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020;22:100293.
Bonde J , Bottari F , Iacobone AD , et al. Human papillomavirus same genotype persistence and risk: a systematic review. J Low Genit Tract Dis. 2020;24:1-13.
Hesselink AT , Sahli R , Berkhof J , et al. Clinical validation of Anyplex II HPV HR detection according to the guidelines for HPV test requirements for cervical cancer screening. J Clin Virol. 2016;76:36-39.
Oštrbenk A , Xu L , Arbyn M , Poljak M. Clinical and analytical evaluation of the Anyplex II HPV HR detection assay within the VALGENT-3 Framework. J Clin Microbiol. 2018;56(11).
Baasland I , Romundstad PR , Eide ML , Jonassen CM . Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population. PLoS One. 2019;14(1):e0210997.
Kang WD , Oh MJ , Kim SM , Nam JH , Park CS , Choi HS . Significance of human papillomavirus genotyping with high-grade cervical intraepithelial neoplasia treated by a loop electrosurgical excision procedure. Am J Obstet Gynecol. 2010;203(1):72.e1-72.e6. https://doi.org/10.1016/j.ajog.2010.01.063
Kocken M , Uijterwaal MH , de Vries AL , et al. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol Oncol. 2012;125(2):500-507. https://doi.org/10.1016/j.ygyno.2012.01.015
Söderlund-Strand A , Kjellberg L , Dillner J. Human papillomavirus type-specific persistence and recurrence after treatment for cervical dysplasia. J Med Virol. 2014;86(4):634-641. https://doi.org/10.1002/jmv.23806
Heymans J , Benoy IH , Poppe W , Depuydt CE , Type-specific HPV . geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. Int J Cancer. 2011;129(4):903-909. https://doi.org/10.1002/ijc.25745
Bosch FX , Lorincz A , Munoz N , Meijer CJ , Shah KV . The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-265.
Geraets D , Alemany L , Guimera N , et al, RIS HPV TT Study Group. Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. J Pathol. 2012;228(4):534-543.